Børs
BørsAksjeliveTips oss!
Oslo1 141,952,93%Olje$ 75,481,31%S&P 5003 970,990,56%USD10,48 kr-EURO11,28 kr-Hong Kong19 915,680,67%Stockholm2 087,812,26%Nasdaq11 823,960,31%--
Markedsoversikt
Min oversikt
Aksjer
Fond
Valuta
Råvarer
Indekser

ULTIMOVACS

ULTI

110,40 NOK
-2,60 (↓ 2,30%)
  • Tid24. mar.
  • Markedsverdi3,80 mrd.
  • Kjøp106,00
  • Selg113,20
  • Høy112,80
  • Lav110,00
  • Volum27 177,00
  • Omsetning3,02 mill.
Dag
Uke
Mnd
YTD
År
3 år
5 år
10 år
Ordredybde
VolumKjøp SelgVolum
195106,00
113,2035
300103,60
120,8050
100103,00
122,00200
20099,80
134,4060
6599,00
135,0011
Børsmeldinger
24. mar 202310:00
Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023
24. mar 202307:00
Ultimovacs ASA: Annual Report 2022
27. feb 202307:00
Ultimovacs to Present at Cowen Healthcare Conference →
27. feb 202307:00
Ultimovacs to Present at Cowen Healthcare Conference
16. feb 202307:00
Ultimovacs ASA Reports Fourth Quarter 2022 Financial Results and Provides General Business Update
09. feb 202307:00
Ultimovacs ASA: Invitation to fourth quarter 2022 results webcast presentation
23. jan 202307:00
Ultimovacs Announces Completed Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma
21. des 202209:27
Financial calendar →
20. des 202207:00
Cemiplimab to replace pembrolizumab in UV1 Phase II LUNGVAC Trial →
20. des 202207:00
Cemiplimab to replace pembrolizumab in UV1 Phase II LUNGVAC Trial
Finanskalender
DatoHendelse
19. aprOrdinær generalforsamling
09. maiKvartalsrapport - Q1
21. augHalvårsrapport
07. novKvartalsrapport - Q3
13. febKvartalsrapport - Q4
20. marÅrsrapport
Om selskapet
Ultimovacs ASA logo
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a therapeutic cancer vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 may serve as a platform for use in combination with other immunotherapy drugs across multiple cancer types. Ultimovacs is performing a development program with clinical trials in Europe and the USA.
Ultimovacs ASA
ULTI
+47 413 80 080
www.ultimovacs.com
Organisasjonummer
996713008
ISIN
NO0010851603
Innsidere
NavnStilling
Leiv AskvigStyremedlem
Eva DugstadStyremedlem
Ketil FjerdingenStyremedlem
Kari GrønåsStyremedlem
Aitana PeireStyremedlem
Største eiere
EierAndel
GJELSTEN HOLDING AS
18,89%
CANICA AS
7,87%
WATRIUM AS
5,18%
INVEN2 AS
4,52%
FOLKETRYGDFONDET
4,41%
RADFORSK INVESTERINGSSTIFTELSE
4,40%
LANGØYA INVEST AS
4,04%
HELENE SUNDT AS
2,81%
CGS HOLDING AS
2,56%
SUNDT AS
2,34%
Andre
43,00%